Archive

Enhancing rural healthcare delivery in India: eSanjeevani and the community health officer perspective.

Response rate was 88.3% (n=106). Daily use by 53.77%; usefulness: skin 50.9%, paediatric 45.3%, maternal 42.5%, diabetes 39.6%, hypertension 38.7%; limitations: specialist availability 58.49%, connectivity 22.64%, extended waiting times 15.1%.

Medicine · National medical journal of India · 12d

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Event-free survival not significantly improved (HR 0.80, 95% CI 0.062-1.03; P=0.083; 4-year EFS difference 3.3%). Overall survival HR 0.86 (95% CI 0.62-1.19).

Oncology · Nature Medicine · 12d

Molecular subtyping and POLE mutation spectrum in endometrial carcinoma.

Molecular classification found POLE ultra-mutated 3.8% (n=2), MMR-deficient 18.9% (n=10), p53-abnormal 17.0% (n=9), and NSMP 37.7% (n=20). POLE sequencing found 11 exonuclease domain variants; V411L was 3.8% (n=2).

Medicine · Indian journal of medical research · 12d

Carbapenem-resistant and other multidrug-resistant organisms in a South Indian tertiary care centre: A laboratory-based study.

Of 8,704 specimens, 3,450 (39.6%) culture-positive; 750 (34.2%) multidrug-resistant. CRE 65.3%, mortality 191/750 (25.5%).

General Medicine · Indian journal of medical research · 12d

Antifungal therapy improves microbiome dynamics in inflammatory bowel disease.

Fluconazole reduced intestinal Candida burden and reshaped fungal composition, increased bacterial diversity, and improved disease activity indices with decreased risk of progression over 8 weeks; nystatin had no effect.

Gastroenterology · Nature Medicine · 12d

Decreasing contamination rates in blood cultures: A plan-do-study-act approach.

Contamination decreased from 10.7% to 3.4% (p<0.0001) after implementing training and supervised collection.

Medicine · National medical journal of India · 12d

Occupational wood dust exposure and lung function impairment: A systematic review and meta-analysis.

Workers exposed to wood dust had lower FEV1 percentage predicted (pooled MD -8.57; 95% CI -12.07 to -5.08; 16 studies), FVC percentage predicted (pooled MD-7.43; 95% CI -11.35 to -3.51; 14 studies), and PEFR percentage predicted (pooled MD -13.43; 95% CI -25.14 to -1.72; 9 studies).

Medicine · National medical journal of India · 12d

Systematic review of medical audits of hysterectomy practices in India.

Hysterectomies were mostly in premenopausal women; one-fourth in women under 40. Leading indications: abnormal uterine bleeding and fibroids. Oophorectomy often done without documented ovarian pathology.

Medicine · Indian journal of medical research · 12d

Empowering accredited social health activist (ASHA) workers to support community mental health in Karnataka State of India: A systematic review.

Improved provider competencies and service delivery outcomes; digital and hybrid models showed more sustained gains than standalone in-person training.

Psychiatry · Indian journal of medical research · 12d

Drug-related calls received at National Poisons Information Centre, India: A 5-year retrospective record-based study.

Drug-related calls were 24% of total calls; 99% were made by treating physicians. Calls increased during Covid-19, with more calls for children and adolescents and fewer for infants; males were 57% and females 41%.

Medicine · National medical journal of India · 12d

McKesson confirms cybersecurity incident as hackers claim millions of patient records stolen

Patient data may be exposed; verify your practice's third-party vendor security and inform patients of potential risks.

General Medicine · Fierce Healthcare · 12d

UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies

If you prescribe CAR-T for autoimmune conditions, expect regulatory scrutiny and enrollment holds—reassess patient risk and alternatives.

General Medicine · Fierce Biotech · 12d

Docs are seeing more patients influenced by mis- and disinformation. What can they do about it?

Prepare to spend more visit time correcting false beliefs; consider brief motivational interviewing and trusted sources to counter harm.

General Medicine · Fierce Healthcare · 12d

ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM

For cardiologists managing ATTR-CM, this suggests RNAi may still benefit patients on tafamidis despite the Wainua failure—watch for confirmatory data.

Cardiology · Fierce Biotech · 12d

Solera Health adds Noom to weight management offerings

Expands patient access to structured weight-loss programs and GLP-1 support, potentially improving adherence and outcomes in obesity care.

Endocrinology · Fierce Healthcare · 12d

ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial

Oral relaxin agonist improved cardiac function in chronic heart failure—watch for a potential new add-on beyond standard therapy.

Cardiology · Fierce Biotech · 12d

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Watch for a new class that removes pathogenic autoantibodies—could shift refractory autoimmune management beyond broad immunosuppression.

General Medicine · Fierce Biotech · 12d

Natera teams with Angiex on cancer drug trial monitoring

Signatera may let you track molecular response to Angiex's investigational therapy, guiding earlier treatment decisions in your cancer patients.

Oncology · Fierce Biotech · 12d

Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark.

Primary endpoint occurred in 139/499 (28%) intervention vs 128/501 (26%) control (HR 1.10, 95% CI 0.86-1.39; p=0.45). No benefit.

Cardiology · Lancet · 13d

Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism.

Primary composite event occurred in 2/280 (0.7%) thrombolysis vs 19/278 (6.8%) standard care (RR 0.10, 95% CI 0.02-0.44, P<0.001), driven by reduced cardiorespiratory decompensation. Major bleeding 1.4% vs 2.2% (P=0.54).

Cardiology · NEJM · 13d

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

In HFrEF, ARNI+SGLT2i+sMRA reduced SBP by -9.2 (-10.6 to -7.8) mmHg, eGFR by -6.8 (-7.9 to -5.4) ml/min/m2, increased potassium by +0.30 (0.25-0.35) mmol/l. In HFmrEF/HFpEF, SGLT2i+sMRA reduced SBP -5.9 (-7.3 to -4.6) mmHg, eGFR -7.7 (-8.9 to -6.4), potassium +0.34 (0.29-0.38).

Cardiology · Nature Medicine · 13d

FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

For patients with polycythemia vera, rusfertide offers a new option to control red cell production, potentially reducing phlebotomy burden.

Oncology · FDA — Press Announcements · 29 Aug

BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test

Adjuvant-only mRNA vaccines may harm; check trial arms before offering off-protocol, especially after Keytruda-paired successes.

Oncology · Fierce Biotech · 28 Aug

Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data

A UCN2 analog may preserve lean muscle during weight loss—unlike GLP-1s—so watch for trials if you manage obesity.

Endocrinology · Fierce Biotech · 28 Aug

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

First oral option for adult dermatomyositis; consider as an alternative to chronic steroids or immunosuppressants in refractory cases.

General Medicine · FDA — Press Announcements · 28 Aug

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

For patients with KRAS-mutant metastatic pancreatic cancer, this RAS inhibitor offers a new targeted option where chemotherapy has been the only mainstay.

Oncology · FDA — Press Announcements · 26 Aug

Critical care utilisation, and outcomes of critically ill obstetric patients in India: a multicentre ICU registry study (2019-2024).

Obstetric ICU mortality was 3.3% versus 7.9% in non-obstetric women (ASD 0.2). Public ICUs had higher crude mortality (6.4% vs 2.1%) but comparable risk-adjusted outcomes.

Obstetrics & Gynaecology · Lancet regional health. Southeast Asia · 26 Aug

FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar

For your diabetic patients, this single wearable replaces separate glucose and ketone sensors, enabling earlier detection of ketoacidosis risk.

Endocrinology · FDA — Press Announcements · 25 Aug

Antimicrobial susceptibility of priority bacterial pathogens from laboratory samples in Timor-Leste: a retrospective analysis of database (2020-2025).

Ceftriaxone susceptibility was 65% (410/631) in E. coli and 25% (135/541) in K. pneumoniae. Meropenem susceptibility in E. coli fell from 100% (33/33) in 2020 to 87% (155/178) in 2024 (p=0.0002).

General Medicine · Lancet regional health. Southeast Asia · 20 Aug

FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia

First gene therapy for GSDIa; consider referring eligible patients aged 8+ for this one-time option to reduce metabolic crises.

General Medicine · FDA — Press Announcements · 20 Aug

FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device

Automates phlebotomy, reducing needle-stick errors and freeing staff—consider workflow impact if adopted in Indian hospitals.

General Medicine · FDA — Press Announcements · 19 Aug

FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices

Shaping FDA rules for generative AI devices will influence global standards, affecting your future adoption of AI tools in practice.

Medicine · FDA — Press Announcements · 18 Aug

Trends of congenital rubella syndrome among infants (0-11 months old) in India: a multicentre hospital-based sentinel surveillance (2016-2025).

Laboratory-confirmed CRS in 583 of 8953 (6.5%). Proportion declined from 24.9% in 2017 to 2.5% in 2025. One-year mortality 32.2% (95% CI 26.7-38.4).

Medicine · Lancet regional health. Southeast Asia · 11 Aug